Eikon Therapeutics, INC. (EIKN) — SEC Filings
Latest SEC filings for Eikon Therapeutics, INC.. Recent 8-K filing on Mar 30, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Eikon Therapeutics, INC. on SEC EDGAR
Overview
Eikon Therapeutics, INC. (EIKN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: Eikon Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 1 neutral, 1 mixed. The dominant filing sentiment for Eikon Therapeutics, INC. is neutral.
Filing Type Overview
Eikon Therapeutics, INC. (EIKN) has filed 1 8-K, 1 10-K with the SEC between Mar 2026.
Recent Filings (2)
-
Eikon Therapeutics Files 8-K on Financials
— 8-K · Mar 30, 2026 Risk: low
Eikon Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes financial statement -
Eikon Pushes Oncology Pipeline, Faces Profitability Hurdles
— 10-K · Mar 30, 2026 Risk: high
Eikon Therapeutics, Inc. (EIKN) is a late clinical-stage biopharmaceutical company focused on oncology, led by experienced drug developers Dr. Roger M. Perlmutt
Risk Profile
Risk Assessment: Of EIKN's 2 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 1 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
Key financial metrics from Eikon Therapeutics, INC.'s most recent 10-K filing (Mar 30, 2026):
- Revenue: $0
- Net Income: Not specified
- EPS: Not specified
- Debt-to-Equity: Not specified
- Cash Position: Not specified
- Operating Margin: Not specified
- Total Assets: Not specified
- Total Debt: Not specified
Key Executives
- Dr. Roger M. Perlmutter
- Dr. Roy Baynes
Industry Context
Eikon Therapeutics operates in the highly competitive biopharmaceutical sector, specifically focusing on oncology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the increasing use of targeted therapies, immunotherapies, and combination treatments, as well as advancements in drug discovery platforms like Eikon's SMT system.
Top Tags
financial-results (1) · 8-k (1) · Biotechnology (1) · Oncology (1) · Clinical Trials (1) · Drug Development (1) · Early Stage Biotech (1) · High Risk Investment (1) · SEC Filings (1)
Executive Compensation
From the most recent 10-K filing (Mar 30, 2026):
- Roger M. Perlmutter — Chief Executive Officer and President: $1,000,000
- Roy Baynes — Chief Medical Officer: $750,000
Key Numbers
- Common Stock Outstanding: 54,138,555 — as of March 17, 2026
- par value per share: $0.0001 — Common Stock
- fiscal year ended: 2025 — for this 10-K filing
- new molecular entities: 100+ — developed by leadership team
- TLR dual-agonist: 7/8 — EIK1001 mechanism
Frequently Asked Questions
What are the latest SEC filings for Eikon Therapeutics, INC. (EIKN)?
Eikon Therapeutics, INC. has 2 recent SEC filings from Mar 2026, including 1 8-K, 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EIKN filings?
Across 2 filings, the sentiment breakdown is: 1 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Eikon Therapeutics, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Eikon Therapeutics, INC. (EIKN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Eikon Therapeutics, INC.?
Key financial highlights from Eikon Therapeutics, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EIKN?
The investment thesis for EIKN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Eikon Therapeutics, INC.?
Key executives identified across Eikon Therapeutics, INC.'s filings include Dr. Roger M. Perlmutter, Dr. Roy Baynes.
What are the main risk factors for Eikon Therapeutics, INC. stock?
Of EIKN's 2 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Eikon Therapeutics, INC.?
Forward guidance and predictions for Eikon Therapeutics, INC. are extracted from SEC filings as they are enriched.